Institut für Pathologie, Charité, Campus Mitte, Humboldt Universität Berlin, Charitéplatz 1, D-10117 Berlin, Germany.
Maturitas. 2010 Mar;65(3):183-9. doi: 10.1016/j.maturitas.2009.11.005. Epub 2009 Dec 14.
Within an average observation period of 5-6 years, several clinical trials reported an increased risk of breast cancer due to hormone replacement therapy (HRT). However, it remains disputable, whether the increased rate of breast cancers detected within the given time frame is indeed due to newly induced tumors and thus constitutes HRT-initiated primary breast cancers. Onco-pathologically speaking it appears more likely that HRT stimulates the growth of already existing small tumor nests which - due to their small size - would otherwise go undiagnosed. The major arguments are: In summary, HRT is hence more likely to be a tumor promoter than a de novo-inducer of breast cancers.
在平均 5-6 年的观察期内，几项临床试验报告称，激素替代疗法（HRT）会增加乳腺癌的风险。然而，仍存在争议的是，在给定的时间框架内检测到的乳腺癌发病率的增加是否确实是由于新诱导的肿瘤引起的，因此构成了 HRT 引发的原发性乳腺癌。从肿瘤病理学的角度来看，HRT 更有可能刺激已经存在的小肿瘤巢的生长，由于它们的体积小，否则这些肿瘤将无法被诊断出来。主要论点是：综上所述，HRT 更可能是一种肿瘤促进剂，而不是乳腺癌的新诱导剂。
